转移性乳腺癌
雌激素受体α
医学
雌激素受体
肿瘤科
内科学
乳腺癌
癌症
工作流程
数据库
计算机科学
作者
Elena Guerini-Rocco,Konstantinos Venetis,Giulia Cursano,Eltjona Mane,Chiara Frascarelli,Francesco Pepe,Mariachiara Negrelli,Edoardo Olmeda,Davide Vacirca,Alberto Ranghiero,Dario Trapani,Carmen Criscitiello,Giuseppe Curigliano,Christian Rolfo,Umberto Malapelle,Nicola Fusco
标识
DOI:10.1016/j.critrevonc.2024.104427
摘要
Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected in up to 40 % of patients pretreated with ET in circulating tumor DNA (ctDNA). Data from prospective randomized trials highlight those patients with HR+/HER2- MBC with detectable ESR1 mutations experience better outcomes when receiving novel selective estrogen receptor degraders (SERDs). There is a high need for optimizing ESR1 testing strategies on liquid biopsy samples in HR+/HER2- MBC, including a hugh quality workflow implementation and molecular pathology reporting standardization. Our manuscript aims to elucidate the clinical and biological rationale for ESR1 testing in MBC, while critically examining the currently available guidelines and recommendations for this specific type of molecular testing on ctDNA. The objective will extend to the critical aspects of harmonization and standardization, specifically focusing on the pathology laboratory workflow. Finally, we propose a clear and comprehensive model for reporting ESR1 testing results on ctDNA in HR+/HER2- MBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI